Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290128 · ClinicalTrials.gov registry record · Phase 3
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
A Phase 3 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Polyneuropathy, Inflammatory Demyelinating, Chronic, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT06290128 is a Phase 3 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Polyneuropathy, Inflammatory Demyelinating, Chronic that is actively recruiting participants, run by Sanofi. The registered enrollment target is 140 participants, above the 116-participant average among 4 other Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT06290128, a Phase 3 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Polyneuropathy, Inflammatory Demyelinating, Chronic, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Riliprubart
Study Locations (20)
California
- USC Norris Comprehensive Cancer Center- Site Number : 8400002 - Los Angeles
- University of California Irvine - Manchester Pavilion- Site Number : 8400007 - Orange
Louisiana
- NeuroMedical Clinic of Central Louisiana- Site Number : 8400031 - Alexandria
- Ochsner Medical Center - Jefferson Highway- Site Number : 8400030 - New Orleans
Michigan
- Henry Ford Hospital- Site Number : 8400025 - Detroit
- Michigan State University- Site Number : 8400038 - East Lansing
New York
- Hospital for Special Surgery- Site Number : 8400041 - New York
- Columbia University Irving Medical Center- Site Number : 8400003 - New York
Ohio
- University of Cincinnati Medical Center- Site Number : 8400020 - Cincinnati
- University Hospitals Cleveland Medical Center- Site Number : 8400033 - Cleveland
Pennsylvania
- Penn State Health Milton South Hershey Medical Center- Site Number : 8400042 - Hershey
- Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022 - Philadelphia
Alabama
- Alabama Neurology Associates- Site Number : 8400019 - Homewood
Connecticut
- Yale University School of Medicine- Site Number : 8400018 - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2024-07-12 |
| Est. Completion | 2028-11-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06290128
The ClinicalTrials.gov registry entry for NCT06290128 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 116-participant average among 4 other Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials with a reported enrollment target (21% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Inflammatory Demyelinating Polyradiculoneuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06290128 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Louisiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT06290128 about?
NCT06290128 is a clinical study titled "A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work". The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
What is the current status of trial NCT06290128?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2024-07-12. Estimated completion is 2028-11-20.
What conditions does trial NCT06290128 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic.
What interventions are being tested in trial NCT06290128?
The interventions under investigation include: Placebo (DRUG), Riliprubart (DRUG).
Who is sponsoring clinical trial NCT06290128?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06290128 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
COMPLETED · Phase 3
-
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
RECRUITING
-
Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
All registered trials for this condition
Polyneuropathy, Inflammatory Demyelinating, Chronic
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.